Ocriplasmin "major added value" for VMT treatment

Article

Jetrea, developed by ThromboGenics, offers ?major added value? for the treatment of vitreomacula traction and macular hole, claims the German Institute for Quality and Efficiency in Health Care (IQWiG).

Jetrea, developed by ThromboGenics, offers “major added value” for the treatment of vitreomacula traction and macular hole, claims the German Institute for Quality and Efficiency in Health Care (IQWiG).

Jetrea contains the active substance ocriplasmin and is administered through one intravitreal injection in adults with VMT and macular hole of a diameter less than or equal to 400 microns.

The treatment breaks down the protein fibres, which cause abnormal traction between the vitreous and the macula that causes VMT. It then releases traction and helps to complete vitreous detachment from the macula.

Dr Patrick De Haes, CEO of ThromboGenics, stated, “IQWiG’s assessment confirming the significant additional benefits of Jetrea for VMT validates the importance of our novel drug in treating patients with this major sight-threatening disease.”

“For the first time, patients can be treated at an earlier stage of their disease, rather than having to watch and wait until their symptoms worsen,” continued Dr De Haes. “We, and our partner Alcon, look forward to working with G-BA to ensure that the positive benefits shown by Jetrea are reflected in its final guidance.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.